Systematic review of economic evaluations of Alzheimer’s disease medications

References

• Yaari R, Corey-Bloom J. Alzheimer’s disease. Semin. Neurol.27(1), 32–41 (2007).
   PubMed Web of Science ®Google Scholar
• Fratiglioni L, De Ronchi D, Aguero-Torres H. Worldwide prevalence and incidence of dementia. Drugs Aging15(5), 365–375 (1999).
   PubMed Web of Science ®Google Scholar
• Takeda A, Loveman E, Clegg A et al. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer’s disease. Int. J. Geriatr. Psychiatry.21(1), 17–28 (2006).
   PubMed Web of Science ®Google Scholar
• Farlow MR, Cummings JL. Effective pharmacologic management of Alzheimer’s disease. Am. J. Med.120(5), 388–397 (2007).
   PubMed Web of Science ®Google Scholar
• Kirby J, Green C, Loveman E et al. A systematic review of the clinical and cost-effectiveness of memantine in patients with moderately severe to severe Alzheimer’s disease. Drugs Aging23(3), 227–240 (2006).
   PubMed Web of Science ®Google Scholar
• Loveman E, Green C, Kirby J et al. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer’s disease. Health Technol. Assess.10(1), 1–160 (2006).
   Web of Science ®Google Scholar
• Oremus M, Tarride JE. A systematic review of the use of contingent valuation in Alzheimer’s disease research. Dement. Int. J. Soc. Res. Pract. (2008) (In press).
   Google Scholar
• Antonanzas F, Rive B, Badenas JM et al. Cost-effectiveness of memantine in community-based Alzheimer’s disease patients: an adaptation in Spain. Eur. J. Health. Econ.7(2), 137–144 (2006).
   PubMedGoogle Scholar
• Caro J, Salas M, Ward A et al. Assessing the health and economic impact of galantamine treatment in patients with Alzheimer’s disease in the health care systems of different countries. Drugs Aging21(10), 677–686 (2004).
   PubMed Web of Science ®Google Scholar
• Caro JJ, Salas M, Ward A et al. Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer’s disease in The Netherlands. Dement. Geriatr. Cogn. Disord.14(2), 84–89 (2002).
   PubMed Web of Science ®Google Scholar
• Fagnani F, Lafuma A, Pechevis M et al. Donepezil for the treatment of mild to moderate Alzheimer’s disease in France: the economic implications. Dement. Geriatr. Cogn. Disord.17(1–2), 5–13 (2004).
   PubMed Web of Science ®Google Scholar
• Francois C, Sintonen H, Sulkava R, Rive B. Cost effectiveness of memantine in moderately severe to severe Alzheimer’s disease: a Markov model in Finland. Clin. Drug. Invest.24(7), 373–384 (2004).
   PubMed Web of Science ®Google Scholar
• Green C, Picot J, Loveman E et al. Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer’s disease. Pharmacoeconomics23(12), 1271–1282 (2005).
   PubMed Web of Science ®Google Scholar
• Hauber AB, Gnanasakthy A, Mauskopf JA. Savings in the cost of caring for patients with Alzheimer’s disease in Canada: an analysis of treatment with rivastigmine. Clin. Ther.22(4), 439–451 (2000).
   PubMed Web of Science ®Google Scholar
• Ikeda S, Yamada Y, Ikegami N. Economic evaluation of donepezil treatment for Alzheimer’s disease in Japan. Dement. Geriatr. Cogn. Disord.13(1), 2002 (2002).
   Google Scholar
• Jones RW, McCrone P, Guilhaume C. Cost effectiveness of memantine in Alzheimer’s disease: an analysis based on a probabilistic Markov model from a UK perspective. Drugs Aging21(9), 607–620 (2004).
   PubMed Web of Science ®Google Scholar
• Jonsson L, Lindgren P, Wimo A et al. The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer’s disease: a Markov model. Clin. Ther.21(7), 1230–1240 (1999).
   PubMed Web of Science ®Google Scholar
• Jonsson L. Cost-effectiveness of memantine for moderate to severe Alzheimer’s disease in Sweden. Am. J. Geriatr. Pharmacother.3(2), 77–86 (2005).
   PubMedGoogle Scholar
• Marin D, Amaya K, Casciano R et al. Impact of rivastigmine on costs and on time spent in caregiving for families of patients with Alzheimer’s disease. Int. Psychogeriatr.15(4), 385–398 (2003).
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Hermann RC, Kuntz KM et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer’s disease. Neurology52(6), 1138–1145 (1999).
   PubMed Web of Science ®Google Scholar
• O’Brien BJ, Goeree R, Hux M et al. Economic evaluation of donepezil for the treatment of Alzheimer’s disease in Canada. J. Am. Geriatr. Soc.47(5), 570–578 (1999).
   PubMed Web of Science ®Google Scholar
• Stewart A, Phillips R, Dempsey G. Pharmacotherapy for people with Alzheimer’s disease: a Markov-cycle evaluation of five years’ therapy using donepezil. Int. J. Geriatr. Psychiatry.13(7), 445–453 (1998).
   PubMed Web of Science ®Google Scholar
• Ward A, Caro JJ, Getsios D et al. Assessment of health economics in Alzheimer’s disease (AHEAD): treatment with galantamine in the UK. Int. J. Geriatr. Psychiatry.18(8), 740–747 (2003).
   PubMed Web of Science ®Google Scholar
• Weycker D, Taneja C, Edelsberg J et al. Cost-effectiveness of memantine in moderate-to-severe Alzheimer’s disease patients receiving donepezil. Curr. Med. Res. Opin.23(5), 1187–1197 (2007).
   PubMed Web of Science ®Google Scholar
• Wimo A, Karlsson G, Nordberg A, Winblad B. Treatment of Alzheimer disease with tacrine: a cost-analysis model. Alzheimer. Dis. Assoc. Disord.11(4), 191–200 (1997).
   PubMed Web of Science ®Google Scholar
• Wimo A, Witthaus E, Rother M, Winblad B. Economic impact of introducing propentofylline for the treatment of dementia in Sweden. Clin. Ther.20(3), 552–566 (1998).
   PubMed Web of Science ®Google Scholar
• Caro J, Getsios D, Migliaccio-Walle K et al. Rational choice of cholinesterase inhibitor for the treatment of Alzheimer’s disease in Canada: a comparative economic analysis. BMC Geriatrics3, 6 (2003).
   PubMedGoogle Scholar
• Fenn P, Gray A. Estimating long-term cost savings from treatment of Alzheimer’s disease. A modelling approach. Pharmacoeconomics16(2), 165–174 (1999).
   PubMed Web of Science ®Google Scholar
• Gagnon M, Rive B, Hux M, Guilhaume C. Cost-effectiveness of memantine compared with standard care in moderate-to-severe Alzheimer disease in Canada. Can. J. Psychiatry52(8), 519–526 (2007).
   PubMed Web of Science ®Google Scholar
• Garfield FB, Getsios D, Caro JJ et al. Assessment of Health Economics in Alzheimer’s Disease (AHEAD): treatment with galantamine in Sweden. Pharmacoeconomics20(9), 629–637 (2002).
   PubMed Web of Science ®Google Scholar
• Getsios D, Caro JJ, Caro G et al. Assessment of health economics in Alzheimer’s disease (AHEAD): galantamine treatment in Canada. Neurology57(6), 972–978 (2001).
   PubMed Web of Science ®Google Scholar
• Henke CJ, Burchmore MJ. The economic impact of the tacrine in the treatment of Alzheimer’s disease. Clin. Ther.19(2), 330–345 (1997).
   PubMed Web of Science ®Google Scholar
• Migliaccio-Walle K, Getsios D, Caro JJ et al. Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer’s disease in the United States. Clin. Ther.25(6), 1806–1825 (2003).
   PubMed Web of Science ®Google Scholar
• Teipel SJ, Ewers M, Reisig V et al. Long-term cost-effectiveness of donepezil for the treatment of Alzheimer’s disease. Eur. Arch. Psychiatry. Clin. Neurosci.257(6), 330–336 (2007).
   PubMed Web of Science ®Google Scholar
• Lubeck DP, Mazonson PD, Bowe T. Potential effect of tacrine on expenditures for Alzheimer’s disease. Med. Interface.7(10), 130–138 (1994).
   PubMedGoogle Scholar
• Bachynsky J, McCracken P, Lier D et al. Propentofylline treatment for Alzheimer disease and vascular dementia: an economic evaluation based on functional abilities. Alzheimer. Dis. Assoc. Disord.14(2), 102–111 (2000).
   PubMed Web of Science ®Google Scholar
• Feldman H, Gauthier S, Hecker J et al. Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology63(4), 644–650 (2004).
   PubMed Web of Science ®Google Scholar
• Wimo A, Winblad B. An economic evaluation of donepezil in mild to moderate Alzheimer’s disease: results of a 1-year, double-blind, randomized trial. Dement. Geriatr. Cogn. Disord.15(1), 2003 (2004).
   Google Scholar
• Small GW, Donohue JA, Brooks RL. An economic evaluation of donepezil in the treatment of Alzheimer’s disease. Clin. Ther.20(4), 838–850 (1998).
   PubMed Web of Science ®Google Scholar
• Wimo A, Winblad B, Stoffler A et al. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer’s disease. Pharmacoeconomics21(5), 327–340 (2003).
   PubMed Web of Science ®Google Scholar
• Kronborg AC, Sogaard J, Hansen E et al. The cost of dementia in Denmark: the Odense Study. Dement. Geriatr. Cogn. Disord.10(4), 295–304 (1999).
   PubMedGoogle Scholar
• Neumann PJ, Sandberg EA, Araki SS et al. A comparison of HUI2 and HUI3 utility scores in Alzheimer’s disease. Med. Dec. Making20(4), 413–422 (2000).
   PubMed Web of Science ®Google Scholar
• Green C. Modelling disease progression in Alzheimer’s disease: a review of modelling methods used for cost-effectiveness analysis. Pharmacoeconomics25(9), 735–750 (2007).
   PubMed Web of Science ®Google Scholar
• Courtney C, Farrell D, Gray R et al. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet363(9427), 2105–2115 (2004).
   PubMed Web of Science ®Google Scholar
• Rahkonen T, Eloniemi-Sulkava U, Rissanen S et al. Dementia with Lewy bodies according to the consensus criteria in a general population aged 75 years or older. J. Neurol. Neurosurg. Psychiatry74(6), 720–724 (2003).
   PubMed Web of Science ®Google Scholar
• Reisberg B, Doody R, Stoffler A et al. Memantine in moderate-to-severe Alzheimer’s disease. N. Engl. J. Med.348(14), 1333–1341 (2003).
   PubMed Web of Science ®Google Scholar
• Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res.12(3), 189–198 (1975).
   PubMed Web of Science ®Google Scholar
• Galasko D, Bennett D, Sano M et al. An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis. Assoc. Disord.11(Suppl. 2), S33–S39 (1997).
   PubMed Web of Science ®Google Scholar
• Holmes C, Burns A, Passmore P et al. AD2000: design and conclusions. Lancet364(9441), 1213–1214 (2004).
   PubMedGoogle Scholar
• Getsios D, Migliaccio-Walle K, Caro JJ. NICE cost-effectiveness appraisal of cholinesterase inhibitors: was the right question posed? Were the best tools used? Pharmacoeconomics25(12), 997–1006 (2007).
   PubMed Web of Science ®Google Scholar
• Canadian Agency for Drugs and Technologies in Health. Guidelines for the Economic Evaluation of Health Technologies: Canada (3rd Edition). Canadian Agency for Drugs and Technologies in Health, Ottawa, Canada (2006).
   Google Scholar
• Raina P, Santaguida P, Ismaila A et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann. Intern. Med.148(5), 379–397 (2008).
   PubMed Web of Science ®Google Scholar
• Santaguida PS, Raina P, Booker L et al.Pharmacological Treatment of Dementia. Evidence Report/Technology Assessment No. 97. Agency for Healthcare Research and Quality, MD, USA (2004).
   Google Scholar
• Demers L, Oremus M, Perrault A, Wolfson C. Review of outcome measurement instruments in Alzheimer’s disease drug trials: introduction. J. Geriatr. Psychiatry. Neurol.13(4), 161–169 (2000).
   PubMedGoogle Scholar
• Canadian Study of Health and Aging. Canadian Study of Health and Aging: study methods and prevalence of dementia. CMAJ150(6), 899–913 (1994).
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Kuntz KM, Leon J et al. Health utilities in Alzheimer’s disease: a cross-sectional study of patients and caregivers. Med. Care.37(1), 27–32 (1999).
   PubMed Web of Science ®Google Scholar
• Naglie G, Tomlinson G, Tansey C et al. Utility-based quality of life measures in Alzheimer’s disease. Qual. Life. Res.15(4), 631–643 (2006).
   PubMed Web of Science ®Google Scholar
• Oremus M, Cosby JL, Wolfson C. A hybrid qualitative method for pretesting questionnaires: the example of a questionnaire to caregivers of Alzheimer disease patients. Res. Nurs. Health.28(5), 419–430 (2005).
   PubMed Web of Science ®Google Scholar
• Caro JJ, Getsios D, Migliaccio-Walle K et al. Assessment of health economics in Alzheimer’s disease (AHEAD) based on need for full-time care. Neurology57(6), 964–971 (2001).
   PubMed Web of Science ®Google Scholar
• Drummond MF, McGuire A. Economic Evaluation in Health Care: Merging Theory with Practice. Oxford University Press, Oxford, UK (2001).
   Google Scholar
• Oremus M, Wolfson C, Bergman H, Vandal AC. Physicians’ efficacy requirements for prescribing medications to persons with Alzheimer’s disease. Can. J. Aging26(2), 139–148 (2007).
   PubMedGoogle Scholar